Durham University

FarrSight-Twin Digital Twins Accurately Replicate Cancer Clinical Trial Outcomes

7 months ago

• FarrSight-Twin technology accurately recreates clinical trials using digital twins of cancer patients, potentially reducing the need for extensive real-world testing. • The digital twin technology utilizes biological data from thousands of cancer patients to predict individual responses to treatment. • Simulated clinical studies using FarrSight-Twin accurately predicted the outcomes of actual clinical trials across breast, pancreatic, and ovarian cancers. • Patients receiving treatments predicted as optimal by FarrSight-Twin showed a 75% response rate, compared to 53.5% with alternative treatments.

Digital Twins Accurately Predict Cancer Treatment Effectiveness in Virtual Trials

7 months ago

• Digital twins, created from biological data of thousands of cancer patients, accurately predicted outcomes in simulated clinical trials, offering a potential tool for virtual drug testing. • FarrSight-Twin, a platform utilizing digital twins, demonstrated a 75% response rate when patients received the treatment it predicted as optimal, compared to 53.5% with alternative treatments. • The technology is being developed to predict individual patient responses to chemotherapy, potentially aiding clinicians in selecting the most effective treatments. • An ongoing observational trial is testing the technology's ability to predict treatment response in patients with triple-negative breast cancer.

Digital Twins Accurately Predict Cancer Treatment Outcomes in Virtual Trials

7 months ago

• Researchers have developed 'digital twins' of cancer patients using the FarrSight®-Twin technology to simulate clinical trials and predict treatment success. • The digital twins, created from extensive patient data, accurately replicated outcomes of actual clinical trials for breast, pancreatic, and ovarian cancers. • When patients received treatments predicted as optimal by their digital twins, response rates improved to 75% compared to 53.5% with alternative treatments. • This technology could expedite drug development by enabling virtual trials and personalized treatment selection, potentially reducing costs and improving patient outcomes.

Digital Twin Technology Accurately Predicts Cancer Treatment Responses in Virtual Clinical Trials

7 months ago

• Researchers have developed FarrSight-Twin, a digital twin technology that recreates clinical trials using virtual replicas of cancer patients. • The technology accurately predicted outcomes in simulated trials across breast, pancreatic, and ovarian cancers, showing potential for optimizing treatment selection. • Digital twins demonstrated a 75% response rate when patients received the predicted optimal treatment, compared to 53.5% with alternative treatments. • This approach could expedite drug development by simulating trials and personalizing treatment plans, potentially reducing costs and improving patient outcomes.

Ellorarxine Shows Promise in Motor Neurone Disease Treatment by Targeting Neuroprotection, Neuroplasticity, and Neurorepair

7 months ago

• A new study reveals that Ellorarxine, a novel compound developed by Nevrargenics Ltd., significantly improves neuronal health in motor neurone disease (MND) patients. • Ellorarxine demonstrates antioxidant and anti-inflammatory effects, increases key protein expression, promotes neurite growth, and enhances mitochondrial health, crucial for combating MND. • The drug uniquely addresses neuroprotection, neuroplasticity, and neurorepair, offering a comprehensive approach rare among potential MND treatments. • Following promising preclinical results, Ellorarxine has received MHRA approval for human trials, marking a significant advancement in MND therapy development.

UK Government Invests in AI and MedTech to Revolutionize Cancer Detection and Treatment

8 months ago

• The UK government is investing in new technologies, including AI, to improve cancer detection and treatment, aiming to boost the life sciences industry. • New partnerships between the NHS, pharmaceutical companies, and universities will trial innovative approaches for faster cancer diagnoses and better treatments. • Funding of £118 million will establish five new health technology hubs across the UK, fostering collaboration between academia and the private sector. • The investments also focus on personalized treatments and utilizing patient data to train AI models for quicker and more accurate cancer diagnoses.